Pipeline Watch: Phase III Readouts In Breast And Liver Cancer Plus COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
Recent executive changes in the industry include C-suite changes at Zentalis Pharmaceuticals and Morphic Holding. Meanwhile, new directors were appointed at SpineThera and Avenue Therapeutics, among others.
Recent executive changes in the industry include C-suite changes at Legend Biotech and Seagen. Meanwhile, new directors were appointed at Alligator Bioscience and Kintor Pharmaceutical, among others.